Physician profile
Byung Lee
NPI 1780975136
$18,313.99
in general payments reported to CMS, 2019-2025
69 companies · $4,951 in 2025
The $4,951 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $565 · 2021: $1,979 · 2022: $1,934 · 2023: $2,771 · 2024: $4,891 · 2025: $4,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Long Term Medical Supply Or Device Loan: $2,299 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,181.93 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $132.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,578.38 | 2019-2025 | |
| Pfizer INC. | $1,544.64 | 2019-2025 | |
| Janssen Biotech, INC. | $1,057.16 | 2019-2025 | Darzalex, Erleada, Imbruvica |
| Eisai INC. | $831.43 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $794.38 | 2019-2025 | Opdivo, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $643.40 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Beigene USA, INC. | $488.20 | 2021-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $464.93 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $463.99 | 2019-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $460.54 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Puma Biotechnology, INC. | $418.76 | 2019-2025 | |
| Array Biopharma INC | $405.93 | 2020-2025 | Mektovi, Braftovi, Tukysa |
| Incyte Corporation | $372.87 | 2020-2025 | Jakafi |
| Lilly USA, LLC | $370.68 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $349.26 | 2019-2025 | Reblozyl, Pomalyst |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $320.80 | 2021-2025 | Xpovio |
| Sobi, INC | $319.35 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $318.70 | 2021-2025 | Fotivda |
| Exelixis INC. | $307.93 | 2021-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.47 | 2019-2025 | Gilotrif |
| Blueprint Medicines Corporation | $249.57 | 2021-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $234.74 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Ipsen Biopharmaceuticals, INC | $206.77 | 2019-2025 | Somatuline Depot, Onivyde, Tazverik |
| Merck Sharp & Dohme LLC | $200.69 | 2019-2025 | Keytruda, Welireg |
| Epizyme, INC. | $193.90 | 2020-2021 | |
| Beone Medicines USA, INC. | $189.18 | 2025 | Brukinsa |
| Secura Bio, INC. | $184.03 | 2020-2024 | Copiktra |
| Alexion Pharmaceuticals, INC. | $181.44 | 2021-2025 | Ultomiris |
| Abbvie INC. | $179.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $172.22 | 2022-2025 | Libtayo |
| Gilead Sciences, INC. | $161.17 | 2021-2024 | |
| Astellas Pharma US INC | $151.78 | 2023-2025 | Xtandi, Xospata, Padcev |
| Genzyme Corporation | $150.83 | 2019-2025 | |
| Amgen INC. | $148.63 | 2019-2023 | Lumakras |
| Taiho Oncology, INC. | $146.51 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $129.17 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $122.18 | 2022-2023 | Adcetris, Padcev |
| Genentech USA, INC. | $116.72 | 2019-2025 | Tecentriq, Polivy |
| Daiichi Sankyo INC. | $106.03 | 2024-2025 | Enhertu, Datroway |
| Pharmaessentia USA Corporation | $104.51 | 2024-2025 | Besremi |
| Emd Serono, INC. | $94.30 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $93.76 | 2024-2025 | Orgovyx |
| Adc Therapeutics America, INC. | $92.50 | 2022-2024 | |
| Springworks Therapeutics, INC. | $72.99 | 2024-2025 | Ogsiveo |
| Verastem, INC. | $70.88 | 2019-2020 | |
| Tersera Therapeutics LLC | $68.06 | 2019 | |
| Deciphera Pharmaceuticals INC. | $61.03 | 2024 | Qinlock |
| Legend Biotech USA INC. | $59.47 | 2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $51.21 | 2024-2025 | Pyrukynd |
| Aurobindo Pharma USA, INC. | $48.12 | 2019 | |
| Mirati Therapeutics, INC. | $38.35 | 2023 | Krazati |
| Clovis Oncology, INC. | $36.75 | 2019 | |
| Insulet Corporation | $34.26 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $31.97 | 2025 | Sancuso |
| Eusa Pharma (US) LLC | $31.95 | 2020-2022 | |
| Syndax Pharmaceuticals, INC. | $28.94 | 2025 | |
| Shield Therapeutics INC | $27.18 | 2025 | |
| Adaptive Biotechnologies Corporation | $26.56 | 2024 | Clonoseq |
| Tolmar Pharmaceuticals, INC. | $26.15 | 2022 | |
| Stemline Therapeutics INC. | $24.20 | 2025 | Orserdu |
| Teva Pharmaceuticals USA, INC. | $23.49 | 2019 | |
| Geron Corporation | $22.80 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $21.22 | 2024 | |
| Recordati_rare_diseases_inc. | $21.20 | 2024 | Sylvant |
| Myriad Genetic Laboratories, INC. | $18.96 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.16 | 2025 | Danziten |
| Morphosys, US INC. | $14.79 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.69 | 2025 | |
| Foundation Medicine, INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.